In the second session of Nanopharm’s fireside series in partnership with FLUIDDA, industry experts Drs. Will Ganley and Eleanor Canipa from Nanopharm and Dr. Jan De Backer from Fluidda provide their thoughts on what the updated PSGs and alternative bioequivalence tell us about the FDA’s position on inhaled generics.
Analytical Services
Rethinking bioequivalence for nasal suspensions: Adopting an in-vitropathway with confidence
Discover how MDRS provides a regulatory-accepted alternative to clinical endpoint studies for nasal suspension bioequivalence. Learn to de-risk your ANDA pathway today.
February 19, 2026
No Comments
